Introduction
============

Marked clinical improvement was reported when a BCR-ABL-kinase inhibitor, imatinib, was combined with chemotherapy for the treatment of Ph-positive (Ph^+^) acute lymphoblastic leukemia (ALL).^[@bib1],\ [@bib2]^ However, further improvement is needed to decrease relapses owing to residual or resistant leukemic cells. Leukemia stem cells (LSCs) are reported to be responsible for leukemia relapse.^[@bib3]^ Mathematical models of the chronic phase of chronic myeloid leukemia suggested that imatinib does not eradicate LSCs,^[@bib4],\ [@bib5]^ and the survival of malignant cells is reportedly attributable to the quiescence of LSCs.^[@bib6]^

In order to overcome drug resistance, rational combinations of molecular targeting drugs of different signal pathways have been explored.^[@bib7]^ The mammalian target of rapamycin (mTOR) has attracted attention as a therapeutic target of LSCs.^[@bib8],\ [@bib9]^ mTOR regulates cell growth and apoptosis through the phosphatidilinositide-3-kinase (PI3K)/AKT/mTOR pathway, which was reported to be constitutively activated in most AMLs^[@bib10]^ or in T-ALL cell lines.^[@bib11]^ The inhibitory effect of an mTOR inhibitor, rapamycin, on the Ph^+^ leukemia cell lines with T315I was reported,^[@bib7]^ and more recently, the effect of everolimus (RAD001) on human childhood B-cell progenitor ALL was reported in a non-obese diabetic/severe combined immunodeficiency (NOD/SCID) model.^[@bib12]^ The mTOR inhibitor everolimus is an orally available mTOR inhibitor which was approved by the Food and Drug Administration for advanced renal cell carcinoma. A phase I/II study has been performed in patients with acute leukemia,^[@bib13]^ and clinical trials alone or in combination with other drugs are also currently ongoing for lymphoma and myeloma.^[@bib14]^ Effects of everolimus on human Ph^+^ ALL have not been well examined.

In this study, we examined the efficacy of everolimus in combination with imatinib utilizing Ph^+^ ALL cell lines and an NOD/SCID/IL2rγ^null^ (NOG) mouse model of human BCR-ABL^+^ leukemia,^[@bib15]^ in which the hierarchy of leukemia cells was maintained.

Materials and methods
=====================

Leukemic cells
--------------

Xenografts were established in NOD/SCID/IL2rγ^null^ (NOG) mice as previously described.^[@bib15]^ Briefly, Ph^+^ ALL patient cells were serially xenotransplanted into immunodeficient NOG mice, and engrafted spleen cells were obtained 8--10 weeks after injection. Erythrocytes were removed by erythrocyte lysis buffer (EL-buffer; Qiagen, Hilden, Germany), and the remaining leukemic cells were preserved in liquid nitrogen until use. Leukemic repopulated cells were thawed and washed, resuspended in RPMI containing 10% fetal bovine serum, 5 m MgCl~2~ and 0.2 mg/ml DNase I (Roche Diagnostics, Mannheim, Germany) and incubated at 37 °C for 10 min. Cells were washed and resuspended at 1 million cells per ml in RPMI containing 20% fetal bovine serum with cytokines (human stem cell factor, 50 ng/ml, human interleukin-3 20 ng/ml and human granulocyte/macrophage-colony-stimulating factor, 20 ng/ml), and incubated with imatinib for 48 h at 37 °C in a CO~2~ incubator. In an *in vitro* long-term culture, spleen (SP) cells derived from leukemic NOG mice were co-cultured with S17 stromal cells and treated with imatinib and everolimus.^[@bib16]^ S-17 cells and leukemic cells were passaged twice weekly.

Reagents
--------

Everolimus and imatinib were supplied by Novartis Institutes for Biomedical Research (Basel, Switzerland). Imatinib was dissolved in dH~2~O and used for *in vitro* and *in vivo* experiments. Everolimus was stored as 10^−2^ M stock solution in dimethylsulfoxide for an *in vitro* experiment. For *in vivo* experiments, everolimus was formulated at 2% (wt/wt) in a microemulsion vehicle. Aliquots of everolimus and control vehicle were stored at −20 °C.

Immunoblotting
--------------

Antibodies against the phospho(p)-Abl (Tyr245), p-CrkL (Tyr207), p-mTOR (Ser2448), p-p70 S6 kinase (Thr389), p-4EBP1 (Thr37/46), MCL-1, p-AKT (Ser473), AKT and p-FOXO1(Thr24)/FoxO3a(Thr32) were from Cell Signaling (Boston, MA, USA). Immunoblotting was performed with the standard protocols as previously described.^[@bib17]^

Flow cytometric analysis and cell sorting
-----------------------------------------

After the treatment period, cells were washed at 4 °C and then stained with anti-CD34-allophycocyanin (APC), anti-CD38-PE-Cy7 (Becton Dickinson, San Jose, CA, USA), and anti-CD45-APC-Alexa Fluor 750 (Invitrogen, Carlsbad, CA, USA) antibodies (1:100) for 30 min on ice. Cells were subsequently labeled with annexin-V-fluorescein isothiocyanate and propidium iodide (PI) according to the manufacturer\'s protocol (Annexin-V-FLUOS Staining Kit; Roche Diagnostics). The cells were acquired by FACS Aria (Becton Dickinson) and analyzed by Flow Jo software. DNA contents analysis was assessed using the standard procedure as previously described.^[@bib18]^ For CD34^+^ selection, leukemic cells were subjected to immunomagnetic separation using a MACS CD34 MicroBead Kit (Miltenyi Biotech, Auburn, CA, USA) following the manufacturer\'s recommendations. The collected cells were applied to a second column and the purification step was repeated. Staining of cells with Hoechst 33342 (Sigma, St Louis, MO, USA) with PyroninY (Polysciences, Warrington, PA, USA) was performed as previously described.^[@bib19]^ Briefly, thawed leukemic spleen cells were separated with the MACS CD34 MicroBead Kit (Miltenyi Biotech) into CD34^+^ cells and flow-through cells containing CD34^−^ cells. MACS-separated cells or drug-treated cells on S17 were washed and stained with Hoechst 33342 and PyroninY, and washed at 4 °C. MACS-separated CD34^+^ cells were then stained with anti-CD38-APC, and flow-through cells containing CD34^−^ cells were stained with anti-CD34-APC. Flow cytometric analysis was performed using FACS Aria.

For cell sorting, leukemic spleen cells were stained with anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Cy7 antibodies and labeled with PI. PI^−^ CD45^+^ cells were sorted for CD34 and CD38 expression using FACS Aria, incubated with treatment drugs for 6 h at 37 °C in a CO~2~ incubator as described above.

Mouse models
------------

### Humanized leukemic mouse model

NOG and NOD/SCID mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan) and Clea Japan (Tokyo, Japan), respectively. Seven-week-old male NOD/SCID mice received 2 Gy of total body irradiation from an X-ray source (MBR-1520R-3; Hitachi Medico Technology Corporation, Tokyo, Japan), 24 h before administration of leukemic 2 × 10^7^ cells. Everolimus (5 mg/kg), imatinib (100 mg/kg) or vehicle were diluted with dH~2~O, and given daily at 10 ml/kg for 10 days by gavage. Bone marrow and spleen cells were stained with anti-human CD19-PE (Becton Dickinson) and anti-mouse CD45-PerCP, and acquired with FACS Aria to analyze chimerism. Cells were also stained with anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Alexa Fluor 750, and were subsequently labeled with annexin-V--fluorescein isothiocyanate and PI as explained above. Protocols were approved by the Nagoya University Animal Ethics Committee.

Histopathology
--------------

Livers, spleens and femurs were fixed in 15% buffered formalin. Hematoxylin and eosin, and CD34 staining were performed as previously described.^[@bib20],\ [@bib21],\ [@bib22]^ Slides were examined at room temperature and images were captured by a fluorescence microscope with a charge-coupled device camera (BZ-8000; Keyence, Osaka, Japan) fitted with × 20 and × 60 objective. Images were acquired by BZ-analyzer software (Keyence).

Statistical analysis
--------------------

Differences among more than two groups were analyzed with the Bonferroni test followed by one-way analysis of variance. Statistical analyses were performed with STATA 9.2 software (StataCorp, College Station, TX, USA).

Results
=======

*Ex vivo* treatment with imatinib for more residual quiescent CD34^+^CD38^−^ population in Ph^+^ ALL cells
----------------------------------------------------------------------------------------------------------

We analyzed the cell cycle status of untreated spleen cells derived from the humanized Ph^+^ ALL leukemia murine model reported previously.^[@bib15]^ In the CD34^+^CD38^−^ population, a higher percentage of Hoechst^low^/PyroninY^low^ slow-cycling quiescent cells was observed than in the CD34^+^CD38^+^ population (*P*\<0.05) and CD34^−^ population (*P*\<0.01). A lower percentage of the S+G~2~/M population was also observed among CD34^+^CD38^−^ cells (*P*\<0.05; [Figure 1a](#fig1){ref-type="fig"}, [Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}).

We next treated these cells with imatinib for 48 h and analyzed the distribution of CD34/CD38 in residual viable cells. After treatment with imatinib at 0.3, 1 and 3 μ, more residual CD34^+^CD38^−^ cells were observed than non-treated cells (12.8 vs 27.2% [Figure 1b](#fig1){ref-type="fig"}, *P*\<0.05; [Supplementary Figure S1b](#sup1){ref-type="supplementary-material"}). Significantly more slow-cycling quiescent (G~0~) cells were observed within CD34^+^38^−^ population after treated with 3 μ of imatinib (*P*=0.03), and less G~0~ cells in CD34^−^ population (*P*=0.02, [Figure 1c](#fig1){ref-type="fig"}).

Treatment of CD34/CD38 sorted cells for 6 h with 3 μ imatinib caused equivalent inhibition of the phosphorylation of BCR-ABL and direct-substrate CrkL in each CD34/CD38 sub-population ([Figure 1d](#fig1){ref-type="fig"}). Inhibition of phosphorylation with imatinib (1 and 3.3 μ) was also observed with intracellular staining of phospho-CrkL ([Supplementary Figure S1c](#sup1){ref-type="supplementary-material"}). Expressions of BCR-ABL and ABL were equivalent in each CD34/CD38 sub-population ([Figure 1d](#fig1){ref-type="fig"}). These results suggested that the slow-cycling population derived from Ph^+^ leukemia NOG mice was insensitive to imatinib in spite of BCR-ABL dephosphorylation.

*Ex vivo* effects of everolimus on leukemic spleen cells, alone and in combination with imatinib
------------------------------------------------------------------------------------------------

Furthermore, we have introduced S-17 murine stromal cell lines to support the leukemic spleen cells in order to assess longer-term effect of treatment drugs,^[@bib16]^ as the CD34^+^ population of leukemic cells from the NOG mice eventually differentiated into CD34^−^ cells and could not be maintained only with cytokines for a longer period. If cultured with S17 cells, leukemic spleen cells were viable for more than 30 days ([Figure 2a](#fig2){ref-type="fig"}).

To examine the potential of everolimus to overcome resistance due to quiescence in Ph^+^ leukemia cells, everolimus treatment was investigated *ex vivo* alone and in combination with imatinib on S17 stromal cells. Everolimus treatment at 100 n for 5 days increased the sub-G~1~ population (14 vs 7.9% control), and combination of everolimus (100 n) and imatinib (1 μ) further increased the sub-G~1~ population (68%, [Figure 2b](#fig2){ref-type="fig"}, upper panel). Cell cycle status was also investigated after treatment with S-17 for 5 days. Although the untreated control and imatinib-treated cells showed 35% of Hoechst^low^/PyroninY^low^ cells in total acquired cells, combination of imatinib and everolimus decreased these quiescent cells to 13% of total acquired cells ([Figure 2b,](#fig2){ref-type="fig"} lower panels). Significant difference was found between imatinib alone and combination of imatinib plus everolimus ([Figure 2c](#fig2){ref-type="fig"}). Treatment with everolimus and imatinib for 5 days induced substantial cell death in CD34^+^38^−^ population relative to dimethylsulfoxide control ([Figure 2d](#fig2){ref-type="fig"}, [Supplementary Figure S1d](#sup1){ref-type="supplementary-material"}). These results indicated that *ex vivo* combination treatment with imatinib and everolimus was also effective for the quiescent CD34^+^38^−^ cells.

Evaluation of molecular biomarkers during cell death induced by treatment with imatinib and everolimus
------------------------------------------------------------------------------------------------------

We next investigated the effects of imatinib and everolimus on BCR-ABL and mTOR signaling. Separated CD34^+^ cells were treated with and without imatinib (1 μ) or everolimus (100 n) for 4 h. After imatinib treatment, phosphorylation of BCR-ABL was clearly inhibited in each population, but it was not affected after everolimus treatment ([Figure 3a](#fig3){ref-type="fig"}). After everolimus treatment, the phosphorylation of S6 K, which is a direct substrate of mTOR, was clearly inhibited; however, the phosphorylation of mTOR and 4EBP1 was not changed ([Figure 3b](#fig3){ref-type="fig"}). These results imply that everolimus inhibited mTOR signaling of CD34^+^ cells and induced cell death independently of the BCR-ABL signaling pathway. Both imatinib alone and in combined treatment inhibited phosphorylation of BCR-ABL. Conversely, everolimus alone and in combination both inhibited phosphorylation of S6 K in both CD34^+^38^−^ and CD34^+^38^+^ sub-populations ([Figure 3c](#fig3){ref-type="fig"}). Everolimus alone or in combination with imatinib decreased the expression of the antiapoptotic BCL-2 family protein, MCL-1, after 4 h, and the combination of everolimus and imatinib also decreased the expression of MCL-1, not BCL-2, after 12 h ([Figure 3c](#fig3){ref-type="fig"}). These results implied that combination treatment with imatinib and everolimus induced cell death in quiescent Ph^+^ leukemia cells.

*In vivo* investigation of effects of everolimus, alone and in combination with imatinib
----------------------------------------------------------------------------------------

To elucidate the *in vivo* efficacy of everolimus treatment, its effects were investigated alone (5 mg/kg) and in combination with imatinib (100 mg/kg+everolimus 5 mg/kg) using NOD/SCID mice intravenously injected with leukemic spleen cells from humanized NOG mouse ([Figure 4a](#fig4){ref-type="fig"}). Percentage of CD19^+^ leukemic cells in peripheral blood was lowest in the imatinib-plus-everolimus-treated group, compared with the vehicle or imatinib alone ([Figure 4b](#fig4){ref-type="fig"}). Overall tumor burden, as assessed by spleen weight ([Figure 4d](#fig4){ref-type="fig"}) and the total number of splenic human CD19^+^ leukemic cells ([Figure 4e](#fig4){ref-type="fig"}), was observed to be lowest in the imatinib-plus-everolimus-treated group. Immunohistochemistry showed that the combination of imatinib plus everolimus decreased the infiltrated CD34^+^ human leukemic cells in spleen, liver and bone marrow ([Figure 4f](#fig4){ref-type="fig"}, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Everolimus alone also decreased the percentage of G~0~ cells in the CD34^+^ leukemic cells of the treated bone marrow ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). These results indicated the *in vivo* efficacy of everolimus treatment in a Ph^+^ leukemia murine model.

Discussion
==========

In this study, we showed the effects of everolimus in combination with imatinib against Ph^+^ ALL quiescent cells. *Ex vivo* imatinib treatment of Ph^+^ leukemia cells from a humanized mouse model showed more residual cells in the CD34^+^CD38^−^ population, which contains significantly more quiescent cells. Our data showed an *ex vivo* effect against these residual cells, and the combination of imatinib and everolimus showed an *in vivo* effect. These data have shown the potential of everolimus to overcome imatinib resistance in quiescent cells. LSCs are reported to be responsible for the resistance to chemotherapy and molecular targeting agents.^[@bib23],\ [@bib24]^ In chronic myeloid leukemia, non-proliferating quiescent CD34^+^ cells have been found to be more resistant than proliferating leukemic cells after treatment with several chemotherapeutic agents.^[@bib25]^ Other studies have shown that inhibitors of mTOR with conventional therapies induced apoptosis and reduced LSCs.^[@bib8]^ The definition of LSCs or cancer stem cells is sometimes controversial in certain diseases. In human AML, LSCs have been phenotypically identified within a CD34^+^CD38^−^ fraction.^[@bib23],\ [@bib26]^ In contrast, it is controversial whether ALL LSCs exist within the CD34^+^ fraction and how CD34, CD38, CD19 and CD133 relate to ALL LSCs.^[@bib15],\ [@bib27],\ [@bib28],\ [@bib29]^ In our current study, the potential of everolimus to overcome imatinib-resistant quiescent cells was demonstrated by using a humanized leukemic mouse model that maintains the differentiation hierarchy of Ph^+^ leukemia.^[@bib15]^ However, it cannot be determined at this point if the real LSCs of Ph^+^ ALL can be diminished until the LSCs in this disease category are clarified.

MCL-1, an antiapoptotic member of the BCL-2 protein family, reportedly regulates the self-renewal of human hematopoietic stem cells as well as LSCs.^[@bib30]^ Mills *et al.*^[@bib31]^ also reported that MCL-1 was translationally regulated by mTORC1. Together with these reports, our results showing decreased expression of MCL-1 by combination treatment of imatinib and everolimus suggested that the combination treatment induced cell death of quiescent Ph^+^ leukemia cells by interfering with the mitochondrial-mediated cell death pathway. Rapamycin and its analogs are also known to induce autophagic cell death,^[@bib32]^ and Bellodi *et al.*^[@bib33]^ reported that target autophagy potentiates tyrosine kinase-induced cell death in Ph^+^ leukemia cells. We are also investigating the relation of autophagy in cell death in our experimental systems.

In this study, everolimus treatment of Ph^+^ leukemia cells from a humanized mouse model decreased the phosphorylation of S6 K, but it increased the phosphorylation of AKT (Ser473) and FOXO1/3a ([Supplementary Figure S4a](#sup1){ref-type="supplementary-material"}). Rapamycin and its analogs, such as everolimus and temsirolimus, are allosteric mTOR inhibitors that function at a distance from the adenosine triphosphate-catalytic binding site. Of the two cellular protein complexes of mTOR molecule, mTORC1 and mTORC2, mTORC1 is sensitive to these allosteric mTOR inhibitors and mTORC2 is resistant.^[@bib34]^ mTORC2 directly activates AKT, and this AKT activation in a feedback loop has been reported to correlate with rapamycin failure.^[@bib35]^ This feedback loop might also be related to our data on upregulated AKT.

Recently, a new generation of mTOR inhibitors has been developed. Dual PI3K/mTOR inhibitors, such as BEZ235, EX147 and PI-103, inhibit PI3 K and both small molecules of mTORC1/2.^[@bib36]^ Adenosine triphosphate-competitive mTOR inhibitors that selectively inhibit TORC1/2 molecules also have been reported to be effective against Ph^+^ transformed leukemia cells and to be less immunosuppressive than PI3K/mTOR inhibitors.^[@bib37]^ The effectiveness of a new generation of mTOR inhibitors should also be investigated in our future studies, in particular, the efficacy of these inhibitors against quiescent or leukemic stem cells using a humanized leukemic mouse model. However, it was suggested that dual PI3K/mTOR inhibitors may cause a greater degree of immune suppression by affecting normal cell functions.^[@bib14]^ Although we have examined the colony formation of CD34^+^ human umbilical cord blood and it was suggested that everolimus did not severely interfere with hematopoietic colony formation (data not shown), the effects of everolimus and the new-generation mTOR inhibitors on normal cells and immune functions must be investigated in future studies.

Acquired mutation in the *BCR-ABL* gene also causes primary and secondary treatment failure in Ph^+^ leukemia. Our data suggest that imatinib-resistant cell lines with T315I mutation ([Supplementary Figures S4b and c](#sup1){ref-type="supplementary-material"}) can be inhibited with everolimus with downregulation of the mTOR pathway ([Supplementary Figure S4d](#sup1){ref-type="supplementary-material"}). The *in vivo* effect of everolimus on T315I-mutated Ph^+^ leukemic cells is also indicated ([Supplementary Figure S4e](#sup1){ref-type="supplementary-material"}). Further study is needed to determine the effect of everolimus on T315I-mutated leukemia, especially in combination with a T315I inhibitor such as AP24534 (ponatinib).^[@bib38]^

In conclusion, we have investigated the imatinib and everolimus combination effect against human Ph^+^ quiescent leukemic cells utilizing a mouse model. Everolimus can improve the treatment of resistant Ph^+^ leukemia. These mice also provide the opportunity to evaluate the effects of new therapeutic modalities on leukemic cells in different stages of cell cycle.
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![*Ex vivo* analysis of humanized mouse positive (Ph^+^) acute lymphoblastic leukemia cells. (**a**) Leukemic spleen cells were CD34 positively selected with MACS column. CD34^+^ cells were stained with Hoechst, PyroninY and CD38-allophycocyanin (APC). Cells including CD34^−^ population that had flowed through the column were stained with Hoechst, PyroninY and CD34-APC. (**b**) Leukemic spleen cells were *ex vivo* cultured with cytokines and treated with or without imatinib (IM) for 48 h. Human CD45^+^ propidium iodide (PI)^−^ Annexin-V^−^ viable population was analyzed for CD34 and CD38 distribution. Panels show a representative experiment. (**c**) After treated with IM for 48 h, CD34^+^ cells were positively selected with MACS column, and stained with Hoechst, PyroninY and CD38-APC. Cells including CD34^−^ population that had flowed through the column were stained with Hoechst, PyroninY and CD34-APC. Graphs show the number of forward scatter/side scatter gated G~0~ cells in each CD34/CD38 sub-population, each relative to the untreated control. Bars indicate mean±s.d. values of three independent experiments (^\*^*P*=0.03 between control and IM 3 μ for CD34^+^ CD38^−^, and ^\*\*^*P*=0.02 between control and IM 3 μ for CD34^−^, by one-way analysis of variance followed by Bonferroni). (**d**) CD34/CD38 sorted populations were treated with or without IM 3 μ for 6 h. Expression of BCR-ABL and phosphorylation of BCR-ABL and CrkL in each population was examined by western blotting analysis.](bcj201116f1){#fig1}

![*Ex vivo* effects of everolimus on leukemic spleen cells in combination with imatinib (IM). (**a**) Leukemic spleen cells were co-cultured with S-17 stromal cells for up to 35 days. Cells were counted with Trypan blue, and viable cells were maintained. (**b**) Cells were treated with or without everolimus (Eve, 100 n) and imatinib (1 μ) alone and in combination for 5 days on S-17 cells. DNA contents were assessed (upper panels) and Hoechst/PyroninY cell cycle analysis (lower panels) was performed. (**c**) Percentages of G~0~ population in total acquired cells were compared with dimethylsulfoxide (DMSO) control after 5-day treatment with imatinib (1 μ), everolimus (100 n) or in combination. Graph shows the means±s.d. values of three independent experiments (^\*^*P*\<0.05 by one-way analysis of variance followed by Bonferroni). (**d**) In the stromal-culturing system, leukemic spleen cells were treated with DMSO (upper column) or in combination of imatinib and everolimus (lower column) for 5 days. Cells were stained with CD34, CD38, human CD45, propidium iodide, and Annexin-V. Cells were gated for human CD45^+^ and CD34/CD38, and cell viabilities in CD34^+^38^−^ population are shown. Panels show a representative analysis.](bcj201116f2){#fig2}

![Western blot analysis of *ex vivo*-treated leukemic cells. (**a**) CD34^+^ cells were separated with MACS column and cells were treated with and without imatinib (IM, 3 μ) or everolimus (Eve, 300 n) for 4 h. Each sample was lysed and western blotting analysis was performed with each antibody. (**b**) MACS-separated cells were treated with or without everolimus (100 n) for 4 h. Each sample was lysed and western blotting was performed with p-mTOR, p-S6 K, p-4EBP1 antibodies. Immunoblotting by antitubulin was performed for the control. (**c**) CD34^+^38^−^ and CD34^+^38^+^ sorted cells were treated with treatment drugs for 4 or 12 h. Each sample was lysed and western blotting analysis was performed with each antibody.](bcj201116f3){#fig3}

![*In vivo* effects of everolimus on leukemic spleen cells in combination with imatinib. (**a**) Non-obese diabetic/severe combined immunodeficiency ( mice were irradiated (IR), and leukemic spleen (SP) cells from NOG (2 × 10^7^) were injected. Experiments were performed twice with three in each treatment group. Control vehicle (*n*=6), imatinib 100 mg/kg (*n*=6), everolimus 5 mg/kg (*n*=6) or a combination of both (*n*=6) were administered for 10 days, and mice were dissected 24 h after the last administration on day 28 following the tumor injection. (**b**, **c**) Percentages of CD19^+^ cells in peripheral blood (**b**) and bone marrow (**c**) are shown, respectively. (**d**) Spleen weight was relatively compared with the average of control mice in each experiment. Bars indicate average of spleen weight in each study group. (**e**) CD19^+^ leukemic spleen cell numbers were relatively compared with the average of control (**b--e**: ^\*^*P*\<0.001, ^\*\*^*P*\<0.005 and ^\*\*\*^*P*\<0.05 by one-way analysis of variance followed by Bonferroni). (**f**) Hematoxylin and eosin (HE) staining (left panels) and immunohistochemical analysis with CD34 (right panels) of the spleen from control mice and imatinib and/or everolimus-treated mice were performed. A charge-coupled device camera provided images at approximately × 100 of the original magnification.](bcj201116f4){#fig4}
